FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024764096> ?p ?o ?g. }

• W2024764096 abstract "Background Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) available for chronic myeloid leukaemia (CML) treatment. Newer drugs, with a faster and better response, were subsequently developed. Purpose To analyse the effectiveness and safety of imatinib in CML patients. Material and methods Retrospective, observational study. Patients who picked up imatinib in our hospital (June 2011–June 2014), including those who were subsequently changed to second generation (2G)–TKI, were included. Variables included demographics (sex, age) and clinical data (time since diagnosis, reason for termination, 2G–TKI received). Adverse drug reactions (ADRs) were compiled in relation to safety. In terms of effectiveness, we considered complete haematological and cytogenetic response and major molecular response (CHR, CCR, MMR) in patients who continued with imatinib at the time of the data compilation. Data was compiled through the electronic prescription programme and medical records. Results We analysed 48 patients. 45.8% (n = 22) were male, with a mean age of 58.7 (9–82). Mean time since diagnosis was 8.2 years (3–13). 31 patients continued with imatinib when data were collected. The 17 remaining changed to 2G–TKIs (10 to nilotinib, 7 to dasatinib). Reasons for termination were: intolerance (n = 9); failure and intolerance (n = 5), loss of response (n = 1), and inclusion in a clinical trial (n = 2). Notified ADRs in our 48 patients were: skin rash-pruritus (4), musculoskeletal pain-myalgia (8), oedema (11, 8 palpebral), gastrointestinal problems (3), haematological reactions (2), other (5). Effectiveness in patients who continued with imatinib was: 27 patients presented CHR, CCR, MMR; 1 had just died, 3 had no data available. Conclusion A considerable proportion of our patients continue with imatinib, and currently present a MMR. The main reason for termination was intolerance. All the notified ADRs were included as frequent or very frequent in the Summary of Product Characteristics. Even with the development of newer drugs, imatinib demonstrated a good profile among our patients and continues to be a good alternative for CML treatment. References and/or Acknowledgements No conflict of interest." @default.
• W2024764096 created "2016-06-24" @default.
• W2024764096 creator A5011420908 @default.
• W2024764096 creator A5048012805 @default.
• W2024764096 creator A5057640513 @default.
• W2024764096 creator A5065086080 @default.
• W2024764096 creator A5077044534 @default.
• W2024764096 creator A5077107154 @default.
• W2024764096 date "2015-03-01" @default.
• W2024764096 modified "2023-09-22" @default.
• W2024764096 title "CP-044 Effectiveness and safety of imatinib in chronic myeloid leukaemia in a tertiary hospital" @default.
• W2024764096 doi "https://doi.org/10.1136/ejhpharm-2015-000639.42" @default.
• W2024764096 hasPublicationYear "2015" @default.
• W2024764096 type Work @default.
• W2024764096 sameAs 2024764096 @default.
• W2024764096 citedByCount "0" @default.
• W2024764096 crossrefType "journal-article" @default.
• W2024764096 hasAuthorship W2024764096A5011420908 @default.
• W2024764096 hasAuthorship W2024764096A5048012805 @default.
• W2024764096 hasAuthorship W2024764096A5057640513 @default.
• W2024764096 hasAuthorship W2024764096A5065086080 @default.
• W2024764096 hasAuthorship W2024764096A5077044534 @default.
• W2024764096 hasAuthorship W2024764096A5077107154 @default.
• W2024764096 hasConcept C126322002 @default.
• W2024764096 hasConcept C141071460 @default.
• W2024764096 hasConcept C197934379 @default.
• W2024764096 hasConcept C2777413986 @default.
• W2024764096 hasConcept C2777583451 @default.
• W2024764096 hasConcept C2778570526 @default.
• W2024764096 hasConcept C2778616394 @default.
• W2024764096 hasConcept C2778729363 @default.
• W2024764096 hasConcept C2779536868 @default.
• W2024764096 hasConcept C3019892230 @default.
• W2024764096 hasConcept C71924100 @default.
• W2024764096 hasConceptScore W2024764096C126322002 @default.
• W2024764096 hasConceptScore W2024764096C141071460 @default.
• W2024764096 hasConceptScore W2024764096C197934379 @default.
• W2024764096 hasConceptScore W2024764096C2777413986 @default.
• W2024764096 hasConceptScore W2024764096C2777583451 @default.
• W2024764096 hasConceptScore W2024764096C2778570526 @default.
• W2024764096 hasConceptScore W2024764096C2778616394 @default.
• W2024764096 hasConceptScore W2024764096C2778729363 @default.
• W2024764096 hasConceptScore W2024764096C2779536868 @default.
• W2024764096 hasConceptScore W2024764096C3019892230 @default.
• W2024764096 hasConceptScore W2024764096C71924100 @default.
• W2024764096 hasLocation W20247640961 @default.
• W2024764096 hasOpenAccess W2024764096 @default.
• W2024764096 hasPrimaryLocation W20247640961 @default.
• W2024764096 isParatext "false" @default.
• W2024764096 isRetracted "false" @default.
• W2024764096 magId "2024764096" @default.
• W2024764096 workType "article" @default.